FDA Inspection 1000396 — PharmaZell Schweiz GmbH
The FDA completed an inspection of PharmaZell Schweiz GmbH on Jan 19, 2017 in Liestal. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Jan 19, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Liestal (Switzerland)